{"id":"W3101089668","doi":"10.1056/nejmoa2027187","title":"First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1064,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK; Pfizer","keywords":"Crizotinib; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Cancer research; Medicine; Internal medicine; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001881834,0.0001799682,0.0006228249,0.0001320421,0.00004347543,0.00000621325,0.00008661972,0.00005254117,0.0008370893],"category_scores_gemma":[0.0004679251,0.0001037938,0.00007031879,0.0003837851,0.00005256844,0.0001302139,0.00001534994,0.0003726282,0.000002965439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000156517,"about_ca_system_score_gemma":0.0005429093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002374205,"about_ca_topic_score_gemma":0.0003568133,"domain_scores_codex":[0.9985543,0.00003981164,0.000625823,0.0001705753,0.0003949944,0.0002145004],"domain_scores_gemma":[0.9986582,0.0002383409,0.0003026045,0.00009892556,0.0002197005,0.0004822059],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02891268,0.0006824973,0.1819829,0.0007792889,0.001710264,0.007249681,0.04372637,0.006589578,0.004853966,0.0002338339,0.06568062,0.6575984],"study_design_scores_gemma":[0.5287751,0.01937861,0.08511787,0.009748519,0.003743489,0.002028319,0.002029042,0.003361043,0.002099274,0.0003154026,0.3428237,0.0005797039],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.606714,0.01757117,0.003784623,0.3609765,0.001702707,0.001137021,0.00004599905,0.000049659,0.008018327],"genre_scores_gemma":[0.9842443,0.002351634,0.001295176,0.006467469,0.004708517,0.000008022499,0.00001630565,0.00002808876,0.0008804889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6570187,"threshold_uncertainty_score":0.9165541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02574200789427179,"score_gpt":0.3619308581690756,"score_spread":0.3361888502748038,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}